Do not make the mistake of considering psoriasis as dandruff. It is important to know the difference between scalp psoriasis ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

J&J announces positive data from phase 3 ICONIC-TOTALa study of icotrokinra to treat scalp and genital psoriasis: Spring House, Pennsylvania Monday, May 12, 2025, 11:00 Hrs [IST] ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...